Ventripoint Diagnostics Stock Probability of Future Stock Price Finishing Over 6.59

VPT Stock  CAD 0.10  0.01  11.11%   
VentriPoint Diagnostics' future price is the expected price of VentriPoint Diagnostics instrument. It is based on its current growth rate as well as the projected cash flow expected by the investors. This tool provides a mechanism to make assumptions about the upside potential and downside risk of VentriPoint Diagnostics performance during a given time horizon utilizing its historical volatility. Check out VentriPoint Diagnostics Backtesting, VentriPoint Diagnostics Valuation, VentriPoint Diagnostics Correlation, VentriPoint Diagnostics Hype Analysis, VentriPoint Diagnostics Volatility, VentriPoint Diagnostics History as well as VentriPoint Diagnostics Performance.
  
At this time, VentriPoint Diagnostics' Price To Sales Ratio is fairly stable compared to the past year. Price Book Value Ratio is likely to climb to 256.06 in 2024, whereas Price To Operating Cash Flows Ratio is likely to drop (12.77) in 2024. Please specify VentriPoint Diagnostics' target price for which you would like VentriPoint Diagnostics odds to be computed.

VentriPoint Diagnostics Target Price Odds to finish over 6.59

The tendency of VentriPoint Stock price to converge on an average value over time is a known aspect in finance that investors have used since the beginning of the stock market for forecasting. However, many studies suggest that some traded equity instruments are consistently mispriced before traders' demand and supply correct the spread. One possible conclusion to this anomaly is that these stocks have additional risk, for which investors demand compensation in the form of extra returns.
Current PriceHorizonTarget PriceOdds to move over C$ 6.59  or more in 90 days
 0.10 90 days 6.59 
close to zero percent
Based on a normal probability distribution, the odds of VentriPoint Diagnostics to move over C$ 6.59  or more in 90 days from now is close to zero percent (This VentriPoint Diagnostics probability density function shows the probability of VentriPoint Stock to fall within a particular range of prices over 90 days) . Probability of VentriPoint Diagnostics price to stay between its current price of C$ 0.10  and C$ 6.59  at the end of the 90-day period is close to 99 .
Assuming the 90 days horizon VentriPoint Diagnostics has a beta of 0.54. This entails as returns on the market go up, VentriPoint Diagnostics average returns are expected to increase less than the benchmark. However, during the bear market, the loss on holding VentriPoint Diagnostics will be expected to be much smaller as well. Additionally VentriPoint Diagnostics has a negative alpha, implying that the risk taken by holding this instrument is not justified. The company is significantly underperforming the Dow Jones Industrial.
   VentriPoint Diagnostics Price Density   
       Price  

Predictive Modules for VentriPoint Diagnostics

There are currently many different techniques concerning forecasting the market as a whole, as well as predicting future values of individual securities such as VentriPoint Diagnostics. Regardless of method or technology, however, to accurately forecast the stock market is more a matter of luck rather than a particular technique. Nevertheless, trying to predict the stock market accurately is still an essential part of the overall investment decision process. Using different forecasting techniques and comparing the results might improve your chances of accuracy even though unexpected events may often change the market sentiment and impact your forecasting results.
Hype
Prediction
LowEstimatedHigh
0.010.116.60
Details
Intrinsic
Valuation
LowRealHigh
0.000.16.59
Details
Naive
Forecast
LowNextHigh
00.086.56
Details
Bollinger
Band Projection (param)
LowerMiddle BandUpper
0.100.120.14
Details

VentriPoint Diagnostics Risk Indicators

For the most part, the last 10-20 years have been a very volatile time for the stock market. VentriPoint Diagnostics is not an exception. The market had few large corrections towards the VentriPoint Diagnostics' value, including both sudden drops in prices as well as massive rallies. These swings have made and broken many portfolios. An investor can limit the violent swings in their portfolio by implementing a hedging strategy designed to limit downside losses. If you hold VentriPoint Diagnostics, one way to have your portfolio be protected is to always look up for changing volatility and market elasticity of VentriPoint Diagnostics within the framework of very fundamental risk indicators.
α
Alpha over Dow Jones
-0.99
β
Beta against Dow Jones0.54
σ
Overall volatility
0.02
Ir
Information ratio -0.16

VentriPoint Diagnostics Alerts and Suggestions

In today's market, stock alerts give investors the competitive edge they need to time the market and increase returns. Checking the ongoing alerts of VentriPoint Diagnostics for significant developments is a great way to find new opportunities for your next move. Suggestions and notifications for VentriPoint Diagnostics can help investors quickly react to important events or material changes in technical or fundamental conditions and significant headlines that can affect investment decisions.
VentriPoint Diagnostics generated a negative expected return over the last 90 days
VentriPoint Diagnostics has high historical volatility and very poor performance
VentriPoint Diagnostics has some characteristics of a very speculative penny stock
VentriPoint Diagnostics has a very high chance of going through financial distress in the upcoming years
VentriPoint Diagnostics has accumulated 274.38 K in total debt. VentriPoint Diagnostics has a current ratio of 0.55, indicating that it has a negative working capital and may not be able to pay financial obligations in time and when they become due. Debt can assist VentriPoint Diagnostics until it has trouble settling it off, either with new capital or with free cash flow. So, VentriPoint Diagnostics' shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like VentriPoint Diagnostics sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for VentriPoint to invest in growth at high rates of return. When we think about VentriPoint Diagnostics' use of debt, we should always consider it together with cash and equity.
The entity reported the revenue of 49.18 K. Net Loss for the year was (4.87 M) with loss before overhead, payroll, taxes, and interest of (6.27 K).
VentriPoint Diagnostics has accumulated about 713.21 K in cash with (3.8 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.01.
Latest headline from news.google.com: Ventripoint Closes Debt Settlement with Share Issuance - TipRanks

VentriPoint Diagnostics Price Density Drivers

Market volatility will typically increase when nervous long traders begin to feel the short-sellers pressure to drive the market lower. The future price of VentriPoint Stock often depends not only on the future outlook of the current and potential VentriPoint Diagnostics' investors but also on the ongoing dynamics between investors with different trading styles. Because the market risk indicators may have small false signals, it is better to identify suitable times to hedge a portfolio using different long/short signals. VentriPoint Diagnostics' indicators that are reflective of the short sentiment are summarized in the table below.
Common Stock Shares Outstanding156.8 M
Cash And Short Term Investments1.3 M
Shares Float156.4 M

VentriPoint Diagnostics Technical Analysis

VentriPoint Diagnostics' future price can be derived by breaking down and analyzing its technical indicators over time. VentriPoint Stock technical analysis helps investors analyze different prices and returns patterns as well as diagnose historical swings to determine the real value of VentriPoint Diagnostics. In general, you should focus on analyzing VentriPoint Stock price patterns and their correlations with different microeconomic environments and drivers.

VentriPoint Diagnostics Predictive Forecast Models

VentriPoint Diagnostics' time-series forecasting models is one of many VentriPoint Diagnostics' stock analysis techniques aimed to predict future share value based on previously observed values. Time-series forecasting models are widely used for non-stationary data. Non-stationary data are called the data whose statistical properties, e.g., the mean and standard deviation, are not constant over time, but instead, these metrics vary over time. This non-stationary VentriPoint Diagnostics' historical data is usually called time series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the stock market movement and maximize returns from investment trading.

Things to note about VentriPoint Diagnostics

Checking the ongoing alerts about VentriPoint Diagnostics for important developments is a great way to find new opportunities for your next move. Our stock alerts and notifications screener for VentriPoint Diagnostics help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.
VentriPoint Diagnostics generated a negative expected return over the last 90 days
VentriPoint Diagnostics has high historical volatility and very poor performance
VentriPoint Diagnostics has some characteristics of a very speculative penny stock
VentriPoint Diagnostics has a very high chance of going through financial distress in the upcoming years
VentriPoint Diagnostics has accumulated 274.38 K in total debt. VentriPoint Diagnostics has a current ratio of 0.55, indicating that it has a negative working capital and may not be able to pay financial obligations in time and when they become due. Debt can assist VentriPoint Diagnostics until it has trouble settling it off, either with new capital or with free cash flow. So, VentriPoint Diagnostics' shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like VentriPoint Diagnostics sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for VentriPoint to invest in growth at high rates of return. When we think about VentriPoint Diagnostics' use of debt, we should always consider it together with cash and equity.
The entity reported the revenue of 49.18 K. Net Loss for the year was (4.87 M) with loss before overhead, payroll, taxes, and interest of (6.27 K).
VentriPoint Diagnostics has accumulated about 713.21 K in cash with (3.8 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.01.
Latest headline from news.google.com: Ventripoint Closes Debt Settlement with Share Issuance - TipRanks

Additional Tools for VentriPoint Stock Analysis

When running VentriPoint Diagnostics' price analysis, check to measure VentriPoint Diagnostics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy VentriPoint Diagnostics is operating at the current time. Most of VentriPoint Diagnostics' value examination focuses on studying past and present price action to predict the probability of VentriPoint Diagnostics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move VentriPoint Diagnostics' price. Additionally, you may evaluate how the addition of VentriPoint Diagnostics to your portfolios can decrease your overall portfolio volatility.